FOLH1 and neoplasm: The heterogeneity of response to PSMA radioligand therapy (PSMA PRLT) in mCRPC is affected by various factors like baseline PSMA expression and tumor volume, which are assessed by 68Ga-PSMA positron emission tomography/computed tomography (PET/CT) [7]. Higher PSMA intensity predicts better therapy response, while larger tumor volumes indicate poorer outcomes [8].